CN113712990A - Composition and preparation method and application thereof - Google Patents
Composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN113712990A CN113712990A CN202110892769.9A CN202110892769A CN113712990A CN 113712990 A CN113712990 A CN 113712990A CN 202110892769 A CN202110892769 A CN 202110892769A CN 113712990 A CN113712990 A CN 113712990A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- composition
- adenosylmethionine
- dimethyl sulfone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title abstract description 6
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims abstract description 76
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 claims abstract description 35
- 229960001570 ademetionine Drugs 0.000 claims abstract description 35
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 235000013402 health food Nutrition 0.000 claims description 16
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 229920000881 Modified starch Polymers 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000013355 food flavoring agent Nutrition 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 239000000905 isomalt Substances 0.000 claims description 3
- 235000010439 isomalt Nutrition 0.000 claims description 3
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000004386 Erythritol Substances 0.000 claims description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 229920003081 Povidone K 30 Polymers 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000019414 erythritol Nutrition 0.000 claims description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 2
- 229940009714 erythritol Drugs 0.000 claims description 2
- 235000010944 ethyl methyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229920003087 methylethyl cellulose Polymers 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 2
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 208000002193 Pain Diseases 0.000 description 10
- 208000006820 Arthralgia Diseases 0.000 description 9
- 239000003814 drug Substances 0.000 description 7
- 206010003246 arthritis Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000008961 swelling Effects 0.000 description 5
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 238000005842 biochemical reaction Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 210000001503 joint Anatomy 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- SERLAGPUMNYUCK-YJOKQAJESA-N 6-O-alpha-D-glucopyranosyl-D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-YJOKQAJESA-N 0.000 description 3
- 208000032170 Congenital Abnormalities Diseases 0.000 description 3
- 206010023232 Joint swelling Diseases 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010023230 Joint stiffness Diseases 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000022159 cartilage development Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 1
- 206010057178 Osteoarthropathies Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000008621 organismal health Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The application discloses a composition, a preparation method and application thereof. The composition comprises the following components: 6-17 parts by weight of S-adenosylmethionine; 6-17 parts by weight of dimethyl sulfone. The pharmaceutical composition comprises S-adenosylmethionine and dimethyl sulfone in a proper proportion, has a good synergistic effect, and has a good effect of treating and/or preventing osteoarthritis.
Description
Technical Field
The application relates to a composition, a preparation method and application thereof, and belongs to the technical field of health-care food and medicines.
Background
Degenerative osteoarthropathy, also known as osteoarthritis, degenerative arthritis, senile arthritis, hypertrophic arthritis, is a degenerative disease, which is caused by degenerative injury of articular cartilage, reactive hyperplasia of articular margin and subchondral bone, and the like due to aging, obesity, strain, trauma, congenital abnormality of joint, joint deformity and other factors. It is common to the middle-aged and the elderly, and is better at the joints with heavy load and more movement (such as cervical vertebra, lumbar vertebra, knee joint, hip joint, etc.). Excessive weight bearing or use of these joints can promote degenerative changes. The clinical manifestations are slowly developing joint pain, tenderness, stiffness, joint swelling, limited mobility and joint deformity.
The existing methods for treating arthritis mainly comprise non-drug treatment, surgical treatment and drug treatment. Non-drug treatment is mainly to modify the bad lifestyle, moderate exercise, and perform proper physical therapy to enhance the muscular strength by the patient, but these only alleviate symptoms and delay the degeneration of the joints. The operation treatment is mainly performed on patients with serious joint damage in the late stage, and certain operation risks exist.
Therefore, it is imperative to develop a product for treating and preventing osteoarthritis which uses raw materials without any toxic and side effects and has remarkable effects.
Disclosure of Invention
According to one aspect of the present application, there is provided a composition comprising S-adenosylmethionine and dimethyl sulfone in a suitable ratio, with a particularly good synergistic effect, and a good treatment and/or prevention of osteoarthritis.
A composition comprising the following components:
6-17 parts by weight of S-adenosylmethionine;
6-17 parts by weight of dimethyl sulfone.
Optionally, the composition comprises the following components:
8-15 parts by weight of S-adenosylmethionine;
8-15 parts by weight of dimethyl sulfone.
Optionally, the composition comprises the following components:
8-15 parts by weight of S-adenosylmethionine;
10-15 parts by weight of dimethyl sulfone.
Optionally, the composition comprises the following components:
8-12 parts by weight of S-adenosylmethionine;
12-15 parts by weight of dimethyl sulfone.
Optionally, the composition comprises the following components:
8-12 parts by weight of S-adenosylmethionine;
12-15 parts by weight of dimethyl sulfone.
Optionally, the composition comprises the following components:
8-12 parts by weight of S-adenosylmethionine;
10-15 parts by weight of dimethyl sulfone.
Optionally, the composition consists of:
6-17 parts by weight of S-adenosylmethionine;
6-17 parts by weight of dimethyl sulfone.
Optionally, the composition consists of:
8-15 parts by weight of S-adenosylmethionine;
8-15 parts by weight of dimethyl sulfone.
Optionally, the composition consists of:
8-15 parts by weight of S-adenosylmethionine;
10-15 parts by weight of dimethyl sulfone.
Optionally, the composition consists of:
8-12 parts by weight of S-adenosylmethionine;
12-15 parts by weight of dimethyl sulfone.
Optionally, the composition consists of:
8-12 parts by weight of S-adenosylmethionine;
12-15 parts by weight of dimethyl sulfone.
Optionally, the composition consists of:
8-12 parts by weight of S-adenosylmethionine;
10-15 parts by weight of dimethyl sulfone.
S-adenosylmethionine (SAMe) is an important physiologically active substance, and is involved in more than 40 biochemical reactions in an organism, such as gene expression, cell membrane flux to polypeptide synthesis, and the like, and SAMe is involved in so many important biochemical reactions as such complicatedly, thus showing wide and various therapeutic effects and having good curative effects on depression, arthritis, liver dysfunction, and the like. SAMe is the most important methyl donor in the body, methyl is provided through methionine circulation to participate in synthesis and metabolism of various important physiological active substances in the body, such as 5-hydroxytryptamine, acetylcholine, epinephrine, creatine, carnitine, dopamine and the like, and normal emotional activity is maintained; methylation of phospholipids helps to enhance receptor function, increase receptor density, and improve receptor coupling. The S-adenosylmethionine has the functions of diminishing inflammation, relieving pain and repairing tissues, can obviously promote chondrogenesis and relieve joint pain, stiffness and swelling, has no side effect and takes effect quickly.
Dimethyl sulfone (MSM) is a natural non-toxic organic sulfide, and 85% of sulfide exists in the form of dimethyl sulfone in human body, especially cartilage tissue and connective tissue. Dimethyl sulfone relieves joint pain by repairing damaged cells that cause joint pain. Dimethyl sulfone can also prevent transmission of pain nerve signals to some extent; dimethyl sulfone can improve collagen connection, repair injured tissues and increase the effect of cortisol, which is a natural anti-inflammatory hormone in the human body; dimethyl sulfone can inhibit the generation of fibroblasts, the fibroblasts are the main factors causing edema, and MSM can be combined with liquid in swollen tissues to achieve the purpose of relieving swelling.
The composition provided by the application has scientific components and mixture ratio, and has obvious effect of treating osteoarthritis: pain, swelling, stiffness, etc. can be used for preventing and treating diseases.
The composition provided by the application reduces the cost of a single raw material through compatibility and use, and the effect is obviously improved. The traditional Chinese medicine composition has the efficacy of treating osteoarthritis, is beneficial to the health of organisms, is suitable for healthy people and osteoarthritis people, is reasonable in formula, mild in medicine property and suitable for long-term use of more people, and S-adenosylmethionine and dimethyl sulfone in raw materials are matched for use.
According to another aspect of the present application, there is provided the use of a composition as defined in any of the above for the manufacture of a product for the treatment and/or prevention of osteoarthritis.
Optionally, the product for treating and/or preventing osteoarthritis is a pharmaceutical preparation or a health food.
Optionally, in the application, the product for treating and/or preventing osteoarthritis is used in a daily dosage of 1-6 g/day based on the composition.
According to another aspect of the present application, there is provided a pharmaceutical formulation comprising the composition of any one of the above and an adjuvant.
According to another aspect of the present application, there is provided a health food comprising the composition of any one of the above and an adjuvant.
Optionally, the adjuvants include flavoring agents, binders, and glidants;
optionally, the flavoring agent is selected from at least one of sorbitol, isomalt, xylitol, erythritol;
the adhesive is selected from at least one of pregelatinized starch, povidone K30, hydroxypropyl methyl cellulose, ethyl cellulose and sodium carboxymethyl cellulose;
the glidant is selected from at least one of magnesium stearate, tricalcium phosphate, stearic acid, calcium stearate and silicon dioxide;
optionally, the pharmaceutical preparation or health food comprises the following components:
optionally, the pharmaceutical preparation or health food comprises the following components:
optionally, the pharmaceutical preparation or health food comprises the following components:
optionally, the pharmaceutical preparation or health food comprises the following components:
according to another aspect of the present application, there is provided a method for preparing the health food or the pharmaceutical preparation of any one of the above, the method comprising the steps of:
mixing the composition and the auxiliary materials to obtain the health-care food or the pharmaceutical preparation.
The beneficial effects that this application can produce include:
(1) the composition provided by the application is reasonable in compatibility and synergistic by combining S-adenosylmethionine and dimethyl sulfone, so that the treatment effect of the obtained composition on osteoarthritis is remarkably improved.
(2) The composition provided by the application has scientific mixture ratio among the components, and the proportion of S-adenosylmethionine to dimethyl sulfone is controlled to be 6-17: 6-17, the effect of the product can be greatly improved;
Detailed Description
The present application will be described in detail with reference to examples, but the present application is not limited to these examples.
The raw materials in the examples of the present application were all purchased commercially, unless otherwise specified.
As an implementation mode, the invention adopts the following technical scheme:
a composition comprising the components shown in table 1:
TABLE 1 composition comprising
Alternatively, the composition comprises the components as shown in table 2:
TABLE 2 composition of included Components
| Components | Content (wt.) |
| S-adenosylmethionine | 10 parts by weight |
| Dimethyl sulfone | 12 parts by weight |
In the present application, S-adenosylmethionine (SAMe), an important physiologically active substance, is involved in more than 40 biochemical reactions in the body, from gene expression, cell membrane flux to polypeptide synthesis, etc., and SAMe is involved in so many important biochemical reactions as to be complicated, thus exhibiting a wide and diverse therapeutic effects and having a good therapeutic effect on depression, arthritis, hepatic disorder, etc. Meanwhile, SAMe is the most important methyl donor in the body, methyl is provided through methionine circulation to participate in the synthesis and metabolism of various important physiological active substances in the body, such as 5-hydroxytryptamine, acetylcholine, epinephrine, creatine, carnitine, dopamine and the like, and normal emotional activity is maintained; methylation of phospholipids helps to enhance receptor function, increase receptor density, and improve receptor coupling. The S-adenosylmethionine has the functions of diminishing inflammation, relieving pain and repairing tissues, can obviously promote chondrogenesis and relieve joint pain, stiffness and swelling, has no side effect and takes effect quickly.
In the present application, dimethyl sulfone (MSM) is a natural non-toxic organic sulfide, and 85% of sulfide exists in the form of dimethyl sulfone in human body, especially cartilage tissue and connective tissue. Dimethyl sulfone relieves joint pain by repairing damaged cells that cause joint pain. Dimethyl sulfone can also prevent transmission of pain nerve signals to some extent; dimethyl sulfone can improve collagen connection, repair injured tissues and increase the effect of cortisol, which is a natural anti-inflammatory hormone in the human body; dimethyl sulfone can inhibit the generation of fibroblasts, the fibroblasts are the main factors causing edema, and MSM can be combined with liquid in swollen tissues to achieve the purpose of relieving swelling.
Examples 1 to 3 and comparative examples 1 to 2
The formulation of the composition is shown in table 3:
TABLE 3 formulation of the compositions
Preparation of the composition:
and weighing the powder in the embodiment and the proportion according to the weight parts, and uniformly mixing to obtain the corresponding composition.
The preparation method of the health food or the pharmaceutical preparation comprises the following steps:
adding isomalt (50 weight parts), pregelatinized starch (10 weight parts) and magnesium stearate (0.5 weight part) into the corresponding composition respectively to prepare tablets, and the specific steps are as follows: preparing 10 wt% aqueous solution of pregelatinized starch, putting isomaltitol into a high-efficiency wet granulator, uniformly spraying the aqueous solution of pregelatinized starch, stirring at 100 rpm and 1200 rpm, discharging after spraying the aqueous solution of pregelatinized starch, sieving with a 20-mesh sieve for granulation, putting the prepared wet granules into a boiling dryer for drying until the moisture content is less than 5 wt%, granulating with a 2.0 mesh sieve to obtain granules 1, uniformly mixing the prepared granules 1 with the formula amount of S-adenosylmethionine and dimethyl sulfone in a mixing tank to obtain granules 2, mixing for 20 minutes, adding the formula amount of magnesium stearate into the mixing tank, mixing for 5 minutes to obtain total mixed granules, and tabletting the total mixed granules to obtain the finished product.
The advantageous effects of the present application are specifically described below by way of test examples.
Dividing 50 volunteers (arthritis patients) into 5 groups, 10 persons in each group, respectively eating the health food prepared in examples 1-3 and comparative examples 1-2, wherein the administration dosage is that each person takes one part of the corresponding health food (4 g/part by weight of the composition) every day, continuously takes 6 weeks, respectively takes 2 weeks, takes 4 weeks, and takes 6 weeks before taking, and takes joint function test, and adopts WOMAC arthritis index to evaluate the joint pain (the detected pain subclass is pain or discomfort when the person lies in bed at night), wherein 0 represents no pain or limited idle function, then the pain is aggravated along with the increase of the value, 10 represents severe pain (the pain can not be relieved after taking the pain relieving medicine) or limited function (can not stand), the average score of each group is calculated, and the statistical result is shown in Table 4:
table 4 test results of each group
| Group of | Before taking | Is administered for 2 weeks | Is administered for 4 weeks | Is administered for 6 weeks |
| Example 1 | 6.7 | 5.8 | 5.0 | 4.1 |
| Example 2 | 6.8 | 6.1 | 5.5 | 4.6 |
| Example 3 | 6.6 | 6.2 | 5.7 | 4.9 |
| Comparative example 1 | 6.7 | 6.4 | 6.0 | 5.9 |
| Comparative example 2 | 6.8 | 6.6 | 6.1 | 6.0 |
From the above results, it can be seen that the index score is more and faster when the health food of examples 1 to 3 of the present application is taken, which indicates that the synergistic effect among the components of the product can be improved by combining the S-adenosylmethionine and the dimethyl sulfone in a specific ratio, and the health food has a good effect of relieving the arthralgia.
Although the present application has been described with reference to a few embodiments, it should be understood that various changes, substitutions and alterations can be made herein without departing from the spirit and scope of the application as defined by the appended claims.
Claims (10)
1. A composition, comprising the following components:
6-17 parts by weight of S-adenosylmethionine;
6-17 parts by weight of dimethyl sulfone.
2. The composition according to claim 1, characterized in that it comprises the following components:
8-12 parts by weight of S-adenosylmethionine;
10-15 parts by weight of dimethyl sulfone.
3. The composition according to claim 1, characterized in that it consists of:
6-17 parts by weight of S-adenosylmethionine;
6-17 parts by weight of dimethyl sulfone.
4. The composition according to claim 1, characterized in that it consists of:
8-12 parts by weight of S-adenosylmethionine;
10-15 parts by weight of dimethyl sulfone.
5. Use of a composition according to any one of claims 1 to 4 in the manufacture of a product for the treatment and/or prevention of osteoarthritis.
6. Use according to claim 5, wherein the product for the treatment and/or prevention of osteoarthritis is a pharmaceutical preparation or a health food.
7. A pharmaceutical preparation comprising the composition of any one of claims 1 to 4 and an adjuvant.
8. A health food comprising the composition of any one of claims 1 to 4 and an adjuvant.
9. The pharmaceutical formulation or health food according to claim 7 or 8, wherein the excipients comprise a flavoring agent, a binder and a glidant;
preferably, the flavoring agent is selected from at least one of sorbitol, isomalt, xylitol and erythritol;
the adhesive is selected from at least one of pregelatinized starch, povidone K30, hydroxypropyl methyl cellulose, ethyl cellulose and sodium carboxymethyl cellulose;
the glidant is selected from at least one of magnesium stearate, tricalcium phosphate, stearic acid, calcium stearate and silicon dioxide;
preferably, the pharmaceutical preparation or health food comprises the following components:
12-34 parts by weight of the composition;
20-60 parts of a flavoring agent;
1-20 parts by weight of a binder;
0.1-1 part by weight of a flow aid.
10. A process for preparing a nutraceutical or pharmaceutical formulation according to any of claims 7 to 9, comprising the steps of:
mixing the composition and the auxiliary materials to obtain the health-care food or the pharmaceutical preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110892769.9A CN113712990A (en) | 2021-08-04 | 2021-08-04 | Composition and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110892769.9A CN113712990A (en) | 2021-08-04 | 2021-08-04 | Composition and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113712990A true CN113712990A (en) | 2021-11-30 |
Family
ID=78674975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110892769.9A Pending CN113712990A (en) | 2021-08-04 | 2021-08-04 | Composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113712990A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001026646A1 (en) * | 1999-10-08 | 2001-04-19 | Pharmnseas, Inc. | NUTRACEUTICAL PRODUCTS CONTAINING SAMe AND DIETARY SUPPLEMENTS AND METHOD OF MANUFACTURING AND USE THEREOF |
| US20020132780A1 (en) * | 2001-01-12 | 2002-09-19 | Heisey Matthew Thomas | Low carbohydrate compositions, kits thereof, and methods of use |
| CN1674870A (en) * | 2002-06-21 | 2005-09-28 | 皮埃蒙特医药品有限公司 | Liposomes containing biologically active compounds |
| JP2007091662A (en) * | 2005-09-29 | 2007-04-12 | Unitec Foods Co Ltd | Food composition for ameliorating arthralgia |
| US20110020316A1 (en) * | 2009-07-23 | 2011-01-27 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Composition and method to alleviate joint pain |
| CN102481266A (en) * | 2009-09-28 | 2012-05-30 | 李日薰 | Pharmaceutical Composition For Treating And Preventing Diseases Involving Joints And Connective Tissue |
| WO2014031087A1 (en) * | 2012-08-21 | 2014-02-27 | Agricultural Research Develpoment Agency (Public Organization) | Natural synergistic formulations containing andrographis paniculata extracts for supporting the inhibition of cartilate degradation in degenerative joint disease |
-
2021
- 2021-08-04 CN CN202110892769.9A patent/CN113712990A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001026646A1 (en) * | 1999-10-08 | 2001-04-19 | Pharmnseas, Inc. | NUTRACEUTICAL PRODUCTS CONTAINING SAMe AND DIETARY SUPPLEMENTS AND METHOD OF MANUFACTURING AND USE THEREOF |
| US20020132780A1 (en) * | 2001-01-12 | 2002-09-19 | Heisey Matthew Thomas | Low carbohydrate compositions, kits thereof, and methods of use |
| CN1674870A (en) * | 2002-06-21 | 2005-09-28 | 皮埃蒙特医药品有限公司 | Liposomes containing biologically active compounds |
| JP2007091662A (en) * | 2005-09-29 | 2007-04-12 | Unitec Foods Co Ltd | Food composition for ameliorating arthralgia |
| US20110020316A1 (en) * | 2009-07-23 | 2011-01-27 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Composition and method to alleviate joint pain |
| CN102481266A (en) * | 2009-09-28 | 2012-05-30 | 李日薰 | Pharmaceutical Composition For Treating And Preventing Diseases Involving Joints And Connective Tissue |
| WO2014031087A1 (en) * | 2012-08-21 | 2014-02-27 | Agricultural Research Develpoment Agency (Public Organization) | Natural synergistic formulations containing andrographis paniculata extracts for supporting the inhibition of cartilate degradation in degenerative joint disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6767899B1 (en) | Composition and method for treatment of conditions having an inflammatory component | |
| EA012798B1 (en) | Pharmaceutical formulation comprising lanthanum compound | |
| CN101069675A (en) | A method of alleviating signs and symptons of spasticity | |
| CN104645332A (en) | Pharmaceutical composition for relieving and preventing arthritis | |
| CN111467481A (en) | Composition for improving and/or preventing osteoarthritis and application thereof | |
| EP2341900A1 (en) | A medicinal product and treatment | |
| CN105770850A (en) | Health care product for adjuvant treatment of osteoarticular diseases and preparation method of health care product | |
| CN113712990A (en) | Composition and preparation method and application thereof | |
| EP2809306A2 (en) | New pharmaceutical compositions of flurbiprofen and glucosamin | |
| US7871648B2 (en) | Herbal formulation for the treatment of bone fractures and osseous defects | |
| CN103877140A (en) | Application of saussurea involucrate culture in preparation of product for promoting bone health | |
| WO2018107324A1 (en) | Calcium supplement composition for decreasing risk of hypercalcemia and use thereof | |
| CN1044860C (en) | Rheumatism medicine | |
| CN100358536C (en) | Prepn process and formula of compound chondroitin sulfate tablet | |
| WO2021179319A1 (en) | Composition containing hydrolyzed chondroitin sulfate for preventing and treating osteoarthropathy | |
| CN110507623B (en) | Composition containing levothyroxine sodium and application thereof | |
| CN101024029B (en) | Medicine for treating bony arthritis, rheumatism arthritis | |
| CN108309997A (en) | A kind of external-use gel preparation and preparation method thereof for treating urarthritis | |
| CN117357547A (en) | Application of pharmaceutical composition in preparation of medicine for treating rheumatoid arthritis | |
| CN115531365B (en) | Application of chlorogenic acid composition in preparation of medicines for preventing or treating pain | |
| CN114343184A (en) | Preparation method of ammonia sugar composite functional tablet | |
| CN115282248A (en) | Composition for relieving joint pain or treating arthritis, and preparation method and application thereof | |
| RU2200553C2 (en) | Method for treating inflammatory articular syndrome and composition for its embodiment | |
| CN110575454A (en) | Application of alkaloid in preparation of medicine for treating bone related diseases | |
| CN116726141A (en) | Composition for preventing and relieving osteoarthropathy and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |